DrugPatentWatch Database Preview

Details for Patent: 7,820,671

« Back to Dashboard

Which drugs does patent 7,820,671 protect, and when does it expire?

Patent 7,820,671 protects INCIVEK and is included in one NDA.

This patent has one hundred patent family members in thirty-five countries.

Summary for Patent: 7,820,671

Title:	Peptidomimetic protease inhibitors
Abstract:	The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.
Inventor(s):	Babine; Robert Edward (Carlsbad, CA), Chen; Shu Hui (Thousand Oaks, CA), Collado; Ivan (Madrid, ES), Garcia-Paredes; Cristina (Madrid, ES), Glass; John Irvin (Germantown, MD), Guo; Deqi (Carmel, IN), Jin; Ling (Indianapolis, IN), Lamar; Jason Eric (Indianapolis, IN), Parker, III; Raymond Samuel (Doylestown, PA), Snyder; Nancy June (Lizton, IN), Sun; Xicheng David (Broumfied, CO), Tebbe; Mark Joseph (Zionsville, IN), Victor; Frantz (Indianapolis, IN), Wang; Q. May (Indianapolis, IN), Yip; Yvonne Yee Mai (Indianapolis, IN), Perni; Robert B. (Marlborough, MA), Farmer; Luc (Foxborough, MA)
Assignee:	Vertex Pharmaceuticals Incorporated (Cambridge, MA)
Application Number:	10/344,112
Patent Claim Types: see list of patent claims	Compound; Composition;

Drugs Protected by US Patent 7,820,671

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Vertex Pharms	INCIVEK	telaprevir	TABLET;ORAL	201917-001	May 23, 2011		DISCN	No	No			Y	Y

Foreign Priority and PCT Information for Patent: 7,820,671

PCT Information
PCT Filed	August 31, 2001	PCT Application Number:	PCT/US01/26008
PCT Publication Date:	March 07, 2002	PCT Publication Number:	WO02/18369

Non-Orange Book US Patents Family Members for Patent 7,820,671

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,252,923	Peptidomimetic protease inhibitors
8,529,882	Peptidomimetic protease inhibitors

International Patents Family Members for US Patent 7,820,671

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	030591
Austria	431358
Austria	483686
Australia	2001288318